Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Roche had there product approved in england today
https://www.england.nhs.uk/2022/01/lung-cancer-patients-to-benefit-from-revolutionary-new-drug-on-nhs/
Tecentriq is a monoclonal antibody therapy targeting the PD-L1 protein, that is expressed on tumour and tumour-infiltrating cells. Blocking its interaction with the PD-1 receptor on the surface of T cells with an immune checkpoint inhibitor, like Tecentriq, can awaken the T cells to the presence of the tumour and restore their ability to detect and attack the tumour cells. Once awakened the immune response to cancer generally persists in patients, offering durable responses.
Avacta are currently developing Affimer® therapeutics to PD-L1, because we believe they will offer a range of benefits over conventional mAbs such as small size, stability and the possibility to build bi-specifics by combining two immune checkpoint therapies into one molecule to give superior efficacy and a better clinical outcome for the patient. Results from pre-clinical in vivo studies show clinically relevant doses of anti-PD-L1 Affimer proteins were very well tolerated with no adverse effects and good in-serum half-lives, reducing the need for repetitive injections to reach a therapeutically relevant concentration. The Affimer inhibitors were able to significantly reduce tumour growth in a syngeneic mouse model, demonstrating their bioavailability and functionality as therapeutic molecules.
Systemic AUC key - it is indicative of cummulative cardiac exposure. What happens to dox after cleaving. Animal studies were OK but doesn't always translate across. If hadn't been OK in animals I doubt they would progress to human studies. Anyone know how dox eliminated and how fast.
Might be being a bit thick.
Is Mr Smith speaking to investors next week because he wants them to buy existing shares - would cause SP to go up.
If he wants to sell them new shares then that is something different. He would want SP to be high as possible for this though
I don't think the company gets any money if we buy and sell shares in market so why do the roadshows. Have I missed something.
Half way through day and 10% up. The meetings next week should have positive effect on sentiment. Will the IIs on Monday have advantage to those on Tues.
If there is good news then 10% just a start - still thinking if LFD relaunched which would fit with time to create new LFD then we go back to status quo at £1.20 at the least?
Deep verge take over would appear to be classic vertical integration. Would suit both sets of shareholders - seem dependent on each other but two lots of overhead wasteful. Deep verge may have deep pockets very soon - however that will also coincide with micro good news too.
Statistics - need more to tell if there is a true difference. Too few numbers and difference could be chance. Using trends is dubious but nice.
FEV1 would be a key efficacy variable but the sample size is probably not big enough
Study achieved what it set out to do. I wouldn't know what these results mean other than supporting move to phase Iii?